Introduction: Chronic hepatitis C virus (HCV) has become the global “epidemic” with an estimated of 2.5% (177.5 million) people currently infected worldwide. In Ethiopia the pooled prevalence estimated is 2%. HCV infection transmission is associated with Percutaneous (dirty needles, blood transfusions, & hemodialysis, Intranasal cocaine Non-commercial tattooing & body piercing, via contaminated multi-use vials & inadequately sterilized multi-use instruments & syringes.), and Non-percutaneous (sexual). At the same time diabetes is also rapidly emerging as a global health care problem that threatens to reach pandemic levels by 2030. Objective: To assess the seroprevalence of HCV and to identify associated factors among Type II Diabetic patients in Tibebegyon Specialized Hospital, Ethiopia. Methodology. A Hospital-Based Case-Control Study was conducted from April –August 2021. A total of 528 study subjects were included in this study based on double proportion formula with age and sex matching between cases and control. A one-day training session for all data collectors and supervisor was given and the questioner was pre tested for assuring clearness and understandability prior to the actual data collection. Sociodemographic and risk factor data were collected by questionnaire. From serum sample, HCV antibody screening was done by rapid antibody screening test. Data was entered in to SPSS version 25 for final analysis. Result: The prevalence of HCV in type II diabetes and nondiabetic controls was 4.2% and 2.3% respectively. In multivariate analysis, it was indicated that HCV seropositive subjects had almost two times higher risk of developing diabetes as compared to HCV seronegative (AOR =2.03, 95% CI: (0.67, 6.15)) with p value of 0.211. Conclusion: The study confirmed a lower rate of HCV in Type II DM patients in TGSH than previous study in Ethiopia. Which show that hcv infection may be a possible risk factor for type 2DM,but not statistically significant .This finding didn’t not allow to recommend regular screening for HCV infection in type 2 diabetics